CIT-013 is under clinical development by Citryll and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CIT-013’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CIT-013 overview
Monoclonal antibodies are under development for the treatment of rheumatoid arthritis, idiopathic pulmonary fibrosis, hidradenitis suppurativa, colitis ,systemic lupus erythematosus and vasculitis. It targets the deiminated peptide-epitopes (DPE). It is developed based on antibody discovery technology platforms ModiFuse (highly efficient hybridoma electrofusion technology), ModiSelect (B-cell selection technology for low immunogenic or multiple antigen targets) and ModiPhage (proprietary phage display libraries). It is administered through intravenous route.
Citryll overview
Citryll, a pharmaceutical company that engaged in the development and commercialization of therapeutics that target NETosis and NETs. The company is headquartered in The Netherlands.
For a complete picture of CIT-013’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
